These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22943931)
1. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Ericsson H; Röshammar D; Wollbratt M; Heijer M; Persson M; Ueda S; Leonsson-Zachrisson M; Norjavaara E Int J Clin Pharmacol Ther; 2012 Nov; 50(11):765-77. PubMed ID: 22943931 [TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus. Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976 [TBL] [Abstract][Full Text] [Related]
3. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin. Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093 [TBL] [Abstract][Full Text] [Related]
4. Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males. Norjavaara E; Ericsson H; Sjöberg F; Leonsson-Zachrisson M; Sjöstrand M; Morrow LA; Hompesch M J Clin Endocrinol Metab; 2012 Sep; 97(9):3319-25. PubMed ID: 22723318 [TBL] [Abstract][Full Text] [Related]
5. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Kiyosue A; Hayashi N; Komori H; Leonsson-Zachrisson M; Johnsson E Diabetes Obes Metab; 2013 Oct; 15(10):923-30. PubMed ID: 23522182 [TBL] [Abstract][Full Text] [Related]
6. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Wilding JP; Leonsson-Zachrisson M; Wessman C; Johnsson E Diabetes Obes Metab; 2013 Aug; 15(8):750-9. PubMed ID: 23464532 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195 [TBL] [Abstract][Full Text] [Related]
8. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558 [TBL] [Abstract][Full Text] [Related]
9. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484 [TBL] [Abstract][Full Text] [Related]
10. Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study. Zheng S; Shao F; Ding Y; Fu Z; Fu Q; Ding S; Xie L; Chen J; Zhou S; Zhang H; Zhou H; Chen Y; Sun C; Zhu J; Zheng X; Yang T Clin Drug Investig; 2020 Dec; 40(12):1155-1166. PubMed ID: 33125674 [TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Sjöstrand M; Ericsson H; Hartford M; Norjavaara E; Eriksson JW Diabetes Obes Metab; 2013 Jan; 15(1):35-41. PubMed ID: 22958202 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients. Zhai S; Georgy A; Liang Z; Zhi J Clin Pharmacol Drug Dev; 2016 Nov; 5(6):552-556. PubMed ID: 27274007 [TBL] [Abstract][Full Text] [Related]
13. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study. Denney WS; Denham DS; Riggs MR; Amin NB Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481 [TBL] [Abstract][Full Text] [Related]
14. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871 [TBL] [Abstract][Full Text] [Related]
16. Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study. Zhao Y; Xie L; Zhang H; Zhou S; Liu Y; Chen J; Wang L; Wang L; Zhuo L; Wang Y; Ou N; Shao F Clin Ther; 2022 Feb; 44(2):269-281. PubMed ID: 35093240 [TBL] [Abstract][Full Text] [Related]
17. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus. Zhi J; Zhai S J Clin Pharmacol; 2016 Feb; 56(2):231-8. PubMed ID: 26183686 [TBL] [Abstract][Full Text] [Related]
18. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123 [TBL] [Abstract][Full Text] [Related]
20. Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes. Zager MG; Kozminski K; Pascual B; Ogilvie KM; Sun S J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):127-39. PubMed ID: 24578187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]